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CASE REPORT
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Abstract 
Background: The gastrointestinal tract is a relatively common involvement site in lymphoma and, in such cases, 
intestinal perforation is a concern before and during chemotherapy. The prediction of intestinal perforation prior to 
chemotherapy is difficult, and there is no standard strategy to minimize the frequency of severely adverse gastrointes‑
tinal events in lymphoma cases.
Case presentation: The 61‑year‑old female patient had a history of primary central nervous system lymphoma 
(PCNSL), diagnosed histologically as diffuse large B cell lymphoma (DLBCL). We administered six courses of inten‑
sive chemotherapy consisting of high‑dose methotrexate and sequential whole‑brain irradiation (40.5 Gy). After a 
3‑year remission of the PCNSL, the patient’s lymphoma recurred, involving the small intestine. 18F‑FDG‑PET/CT upon 
the recurrence before chemotherapy showed multiple nodular lesions in the patient’s gastrointestinal tract. Central 
nervous system lesions were not detected. We administered intensive salvage chemotherapy consisting of cyclophos‑
phamide, high‑dose AraC, methyl‑prednisolone, etoposide, and rituximab. The response was a rapid partial response, 
but on day 10 after the initiation of salvage chemotherapy, she complained of abdominal pain with tenderness. The 
contrast‑enhanced (CE)‑CT revealed transmural ischemia of the intestine. On the 7th day after the onset of urgent 
abdominal symptoms, follow‑up CE‑CT showed that the ischemic lesion had become thin. We conducted elective 
surgery after waiting for the complete recovery of the patient’s white blood cell count. The pathological findings of 
resected intestine confirmed the elimination of the majority of lymphoma cells and concomitant partial necrotic 
tissue.
Conclusions: We were able to avoid the neutropenic period and safely conducted the surgical treatment for the 
subclinical perforation by using CE‑CT. The combination of 18F‑FDG‑PET/CT before chemotherapy and CE‑CT scan‑
ning for the targeted involvement site helped us evaluate the surgical indications and optimal timing of surgery in a 
lymphoma patient with gastrointestinal involvement.
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Background
The prevalence of gastrointestinal involvement in lym-
phoma is relatively common at 22  % [1]. The incidence 
of intestinal perforation in lymphoma patients in 9 % [2]. 
In lymphoma patients with gastrointestinal involvement, 
a primary surgical intervention should be considered 
before systemic chemotherapy [3, 4] because if chemo-
therapy will be necessary, neutropenia and other chem-
otherapy-induced adverse events might hinder the 
appropriate and optimal surgical intervention [4, 5]. The 
known risk factors for perforation in gastrointestinal 
lymphoma patients were discussed in a review [2] which 
revealed that the small bowel was the most prevalent site 
of perforation and the diffuse large B-cell disease subtype 
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Although the appropriate indications and optimal 
timing of elective surgery have not be determined, it is 
apparent that emergent surgery at the presentation of 
perforation should be avoided because of its high mor-
bidity rate. Additionally, a life-threatening condition 
requiring surgical intervention during chemotherapy is 
associated with an increased risk of morbidity/mortality 
[2].
We offer a combinatory imaging evaluation that can be 
used to estimate the pathological status of gastrointes-
tinal involvement prior to treatment. An exact imaging 
analysis can determine the degree and severity of involve-
ment sites, and it would contribute to clinical decisions 
regarding surgical interventions.
Case presentation
A 61-year-old female had a history of primary central 
nervous system lymphoma (PCNSL), diagnosed histolog-
ically as diffuse large B-cell lymphoma (DLBCL) (Fig. 1). 
We treated her with four cycles of chemotherapy con-
sisting of cyclophosphamide, doxorubicin, vincristine, 
prednisolone, and high-dose methotrexate (M-CHOP), 
and sequential whole-brain irradiation (40.5 Gy). After a 
3-year remission of the PCNSL, the patient’s lymphoma 
recurred as gastrointestinal lesions (Fig.  2). We then 
performed 18F-FDG-PET/CT, which revealed multiple 
nodular lesions of recurrence in her stomach, small intes-
tine, liver, intraceliac lymph nodes, and bones (Fig.  3a). 
Cranial MRI detected no aberrant signals as a recurrent 
lesion of the primary site.
We performed salvage chemotherapy consisting of 
cyclophosphamide, high-dose AraC, methyl-predniso-
lone, etoposide, and rituximab (CHASER). The patient 
then complained of occasional slight abdominal pain after 
eating, but the symptoms did not disturb her food con-
sumption. She did not need any analgesia for her abdom-
inal pain. The patient was afebrile through until day 9 of 
this treatment course. On day 10 of the chemotherapy, 
Fig. 1 Pathological findings at the onset (brain). Hematoxylin‑eosin (HE) staining showed a diffuse infiltration of morphological large lymphocytes 
(magnification 40×) (a). Immunochemical staining revealed positive results for CD20 (b) and CD79a (c) and a negative result for EBER (d)
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gastrointestinal perforation was suspected because of 
abdominal rebound tenderness. Her vital signs on day 10 
were as follows: blood pressure 94/56 mmHg, heart rate 
68/min, body temperature 36.0  °C. An abdominal X-ray 
did not reveal free air. An immediate CT scan depicted 
an enhancement defect of the intestinal wall (Fig.  3b), 
which indicated transmural ischemia of the intestine. The 
patient had multiple intestinal involvements of DLBCL, 
but other infiltration sites of the intestine revealed an 
enhancement effect of intestinal wall, which had been 
thought to be intact.
We stopped her oral intake, and we started admin-
istering meropenem from day 10. From day 14, spike 
fever 38.1–39.5  °C was observed, with blood pressure 
102/52 mmHg and heart rate 75/min. An elective surgery 
was conducted on day 18 after the patient’s white blood 
cell count had risen to >10,000/µL, and we performed a 
partial resection of the small intestine at 10 cm (anal side) 
from the Treitz ligament. We used contrast-enhanced 
(CE)-CT to estimate the surgical indication and optimal 
timing of surgery. The pathological findings elucidated 
the elimination of the majority of lymphoma cells and 
concomitant partial necrotic tissue (Fig. 3c).
Conclusions
The combination of 18F-FDG-PET/CT before chemother-
apy and repeated CE-CT scanning for the targeted involve-
ment site was effective for assessing the surgical indication 
and optimal timing of surgery in this case. The relevant 
role of 18FDG-PET/CT in the delineation of disease-spread 
patterns has been reported in a study [6] and a review [7]. 
Although there few studies describing the specific diagnosis 
and evaluation of small bowel lymphoma, it was reported 
that 18FDG-PET combined with CT is a useful tool for 
Fig. 2 Pathological findings at the recurrence (intestine). HE staining showed a diffuse infiltration of morphological large lymphocytes (magnifica‑
tion as noted) (a). Immunochemical staining revealed positive results for CD20 (b) and CD79a (c) and a negative result for EBER (d), phenotypically 
similar to the primary site, brain (Fig. 1)
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estimating the pathological status of disease [6]. Due to a 
lack of efficacy of 18F-FDG-PET/CT for the evaluation of 
intestinal perforation caused by cancer, we cannot make 
conclusions about the utility of this modality. However, 
18F-FDG-PET/CT is widely applicable for both the localiza-
tion and viability of malignancies [6]. This property plays a 
crucial role in assessing disease activities including inflam-
mation and necrosis. We contend that the estimation by 
Fig. 3 Radiological imaging and pathological findings of the ischemic intestinal site. (a) 18F‑FDG‑PET/CT before the patient’s chemotherapy dem‑
onstrated the involvement of malignant lymphoma in multiple intestine sites and the liver. The open triangle indicates the tissue involvement. (b) 
The 18F‑FDG‑PET image superimposed in red on the CT image obtained before the chemotherapy illustrates the transverse image of the involve‑
ment (left). CT on day 10 after chemotherapy depicting transmural necrosis of the intestine (middle). On day 14 after the initiation of the chemo‑
therapy, the enhancement of intestinal wall on CT were recovering (right). The open triangle indicates the involved intestine. (c) Pathological findings 
of resected intestine confirmed the elimination of the majority of the lymphoma. Macroscopic findings identified the incomplete perforation site 
covered with a thin serous membrane (left column, yellow arrow). The pathological findings elucidated the elimination of the majority of lymphoma 
cells and concomitant partial necrotic tissue (right column)
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FDG-PET before chemotherapy plus repeated CT scanning 
for the targeted involvement site is the best combinatory 
technique for making clinical decisions regarding surgical 
intervention. We should consider this approach for cancer 
patients with an extra-primary site lesion, in whom necro-
sis can be critical to the clinical course.
Although intestinal involvement is not a rare complication 
in lymphoma, clinicians should add a pathological assess-
ment for the etiology of intestinal perforation. Ulcerative 
bowel lesions may be associated with a particular pathologi-
cal subtype. Dojcinov et al. [8] reported a series of Epstein 
Barr virus (EBV)-positive mucocutaneous ulcers associated 
with various types of immunosuppression. These lesions 
are histologically characterized by CD30- and Epstein-Barr 
virus-encoded small RNA (EBER)-positive B cell infiltration, 
sometimes with Hodgkin-like cells. Dojcinov et al. reported 
that this type of ulcerative disease exhibits a self-limited 
indolent clinical course and responds well to conservative 
therapy, including spontaneous remissions. They proposed 
that this EBV-positive mucocutaneous ulcer is an inde-
pendent, newly recognized clinicopathologic entity with 
Hodgkin-like features and discussed its association with 
immunosuppression as a common pathogenic mechanism. 
The localized nature can be managed through treatment. 
We analyzed the EBER staining in our patient’s primary and 
recurrence sites and found that both lesions were pathologi-
cally EBER-negative. It may be helpful to survey other alter-
native factors that may contribute to perforation, for the 
management of intestinal adverse events.
In conclusion, the combination of 18F-FDG-PET/CT 
before chemotherapy and repeated CE-CT scanning for 
the targeted involvement site can be used to estimate the 
surgical indications and optimal timing of surgery. We 
suggest that an elective surgery can rescue lymphoma 
patients with intestinal involvement [9] under prudent 
radiological monitoring.
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